Chris Doyle

Chris Doyle has a diverse work experience spanning various industries and roles. Chris is currently the Chief Financial Officer at Seraphina Therapeutics and fatty15. In their previous role as the Chief Financial Officer at Diggs Pet, they successfully led the finance function and built financial planning and forecasting capabilities. Chris provided performance insight to existing investors and developed strategies for bringing in new capital. Prior to Diggs Pet, they worked at Mars as the Global Finance Director and Senior Finance Manager, where they led financial planning, analysis, and provided financial support for strategic initiatives and investment activities. Chris also has experience in investment banking, where they served as an Investment Banking Associate at Moelis & Company and as a Private Equity Associate at Nebrodi Partners LLC. Chris holds an MBA from Yale School of Management and has a background in securitized products, having worked as an Associate and Analyst at J.P. Morgan.

Chris Doyle attended Fordham Preparatory School from 2001 to 2005. Chris then went on to earn a Bachelor of Arts degree in Economics from Williams College, where they studied from 2005 to 2009. Later, from 2014 to 2016, Chris pursued a Master of Business Administration (MBA) degree at the Yale School of Management.